Survival after phase ii treatment of advanced renal cell carcinoma with taxol or high-dose interleukin-2

E. T. Walpole, J. P. Dutcher, Joseph A. Sparano, Rasim A. Gucalp, Avi Israel Einzig, Elisabeth M. Paietta, N. Ciobanu, K. Grima, G. Caliendo, G. Cavasotto, P. H. Wiernik

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

From 1986 to 1989, 71 patients with advanced renal cell carcinoma were treated at one institution with either the Phase II agent, taxol, or one of several high dose interleukin-2 (IL-2) protocols. As no responses to taxol were seen, that group may represent the natural history of renal cell carcinoma in a Phase II population. The results of treatment with IL-2 were examined against this background. Concurrently, 17 patients received taxol and 14 patients IL-2. An additional 40 patients subsequently received IL-2. Five taxol patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 were excluded from the comparison as similar patients were ineligible for the IL-2 studies. There were more patients in the IL-2 groups with non-liver/lung metastases and ECOG PS 0 than in the taxol group. Six (43%) of concurrent IL-2 patients responded [complete response (CR)=14%; partial response (PR)=29%]. The response rate for all IL-2-treated patients was 22% (CR ± 7%, PR ± 15%). The response rate to IL-2 was higher in cases with ECOG PS 0, time to treatment <12 months, and no prior chemotherapy. The median time to progression for the concurrent IL-2 group was 4.5 months (4.0 months for all IL-2 patients) and 2.5 months for taxol patients. Median survival for concurrent IL-2 patients was 12.5 months (12 months for all IL-2 patients) and 10 months for taxol patients. Durable remissions resulted in a 21% overall survival at 40 months for all IL-2 patients. These data show prolonged time to treatment failure after treatment with IL-2 and evidence of improvement in survival for patients eligible for Phase II studies.

Original languageEnglish (US)
Pages (from-to)275-281
Number of pages7
JournalJournal of Immunotherapy
Volume13
Issue number4
StatePublished - 1993

Fingerprint

Paclitaxel
Renal Cell Carcinoma
Interleukin-2
Survival
Therapeutics
Treatment Failure
Interleukin-10

Keywords

  • Interferon-a
  • Interleukin-2
  • Lymphocyte-activated killer cells
  • Renal cell carcinoma
  • Taxol

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Immunology and Allergy
  • Pharmacology

Cite this

Survival after phase ii treatment of advanced renal cell carcinoma with taxol or high-dose interleukin-2. / Walpole, E. T.; Dutcher, J. P.; Sparano, Joseph A.; Gucalp, Rasim A.; Einzig, Avi Israel; Paietta, Elisabeth M.; Ciobanu, N.; Grima, K.; Caliendo, G.; Cavasotto, G.; Wiernik, P. H.

In: Journal of Immunotherapy, Vol. 13, No. 4, 1993, p. 275-281.

Research output: Contribution to journalArticle

Walpole, ET, Dutcher, JP, Sparano, JA, Gucalp, RA, Einzig, AI, Paietta, EM, Ciobanu, N, Grima, K, Caliendo, G, Cavasotto, G & Wiernik, PH 1993, 'Survival after phase ii treatment of advanced renal cell carcinoma with taxol or high-dose interleukin-2', Journal of Immunotherapy, vol. 13, no. 4, pp. 275-281.
Walpole, E. T. ; Dutcher, J. P. ; Sparano, Joseph A. ; Gucalp, Rasim A. ; Einzig, Avi Israel ; Paietta, Elisabeth M. ; Ciobanu, N. ; Grima, K. ; Caliendo, G. ; Cavasotto, G. ; Wiernik, P. H. / Survival after phase ii treatment of advanced renal cell carcinoma with taxol or high-dose interleukin-2. In: Journal of Immunotherapy. 1993 ; Vol. 13, No. 4. pp. 275-281.
@article{c8d53ab028784a16bff871e1e183daac,
title = "Survival after phase ii treatment of advanced renal cell carcinoma with taxol or high-dose interleukin-2",
abstract = "From 1986 to 1989, 71 patients with advanced renal cell carcinoma were treated at one institution with either the Phase II agent, taxol, or one of several high dose interleukin-2 (IL-2) protocols. As no responses to taxol were seen, that group may represent the natural history of renal cell carcinoma in a Phase II population. The results of treatment with IL-2 were examined against this background. Concurrently, 17 patients received taxol and 14 patients IL-2. An additional 40 patients subsequently received IL-2. Five taxol patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 were excluded from the comparison as similar patients were ineligible for the IL-2 studies. There were more patients in the IL-2 groups with non-liver/lung metastases and ECOG PS 0 than in the taxol group. Six (43{\%}) of concurrent IL-2 patients responded [complete response (CR)=14{\%}; partial response (PR)=29{\%}]. The response rate for all IL-2-treated patients was 22{\%} (CR ± 7{\%}, PR ± 15{\%}). The response rate to IL-2 was higher in cases with ECOG PS 0, time to treatment <12 months, and no prior chemotherapy. The median time to progression for the concurrent IL-2 group was 4.5 months (4.0 months for all IL-2 patients) and 2.5 months for taxol patients. Median survival for concurrent IL-2 patients was 12.5 months (12 months for all IL-2 patients) and 10 months for taxol patients. Durable remissions resulted in a 21{\%} overall survival at 40 months for all IL-2 patients. These data show prolonged time to treatment failure after treatment with IL-2 and evidence of improvement in survival for patients eligible for Phase II studies.",
keywords = "Interferon-a, Interleukin-2, Lymphocyte-activated killer cells, Renal cell carcinoma, Taxol",
author = "Walpole, {E. T.} and Dutcher, {J. P.} and Sparano, {Joseph A.} and Gucalp, {Rasim A.} and Einzig, {Avi Israel} and Paietta, {Elisabeth M.} and N. Ciobanu and K. Grima and G. Caliendo and G. Cavasotto and Wiernik, {P. H.}",
year = "1993",
language = "English (US)",
volume = "13",
pages = "275--281",
journal = "Journal of Immunotherapy",
issn = "1053-8550",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Survival after phase ii treatment of advanced renal cell carcinoma with taxol or high-dose interleukin-2

AU - Walpole, E. T.

AU - Dutcher, J. P.

AU - Sparano, Joseph A.

AU - Gucalp, Rasim A.

AU - Einzig, Avi Israel

AU - Paietta, Elisabeth M.

AU - Ciobanu, N.

AU - Grima, K.

AU - Caliendo, G.

AU - Cavasotto, G.

AU - Wiernik, P. H.

PY - 1993

Y1 - 1993

N2 - From 1986 to 1989, 71 patients with advanced renal cell carcinoma were treated at one institution with either the Phase II agent, taxol, or one of several high dose interleukin-2 (IL-2) protocols. As no responses to taxol were seen, that group may represent the natural history of renal cell carcinoma in a Phase II population. The results of treatment with IL-2 were examined against this background. Concurrently, 17 patients received taxol and 14 patients IL-2. An additional 40 patients subsequently received IL-2. Five taxol patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 were excluded from the comparison as similar patients were ineligible for the IL-2 studies. There were more patients in the IL-2 groups with non-liver/lung metastases and ECOG PS 0 than in the taxol group. Six (43%) of concurrent IL-2 patients responded [complete response (CR)=14%; partial response (PR)=29%]. The response rate for all IL-2-treated patients was 22% (CR ± 7%, PR ± 15%). The response rate to IL-2 was higher in cases with ECOG PS 0, time to treatment <12 months, and no prior chemotherapy. The median time to progression for the concurrent IL-2 group was 4.5 months (4.0 months for all IL-2 patients) and 2.5 months for taxol patients. Median survival for concurrent IL-2 patients was 12.5 months (12 months for all IL-2 patients) and 10 months for taxol patients. Durable remissions resulted in a 21% overall survival at 40 months for all IL-2 patients. These data show prolonged time to treatment failure after treatment with IL-2 and evidence of improvement in survival for patients eligible for Phase II studies.

AB - From 1986 to 1989, 71 patients with advanced renal cell carcinoma were treated at one institution with either the Phase II agent, taxol, or one of several high dose interleukin-2 (IL-2) protocols. As no responses to taxol were seen, that group may represent the natural history of renal cell carcinoma in a Phase II population. The results of treatment with IL-2 were examined against this background. Concurrently, 17 patients received taxol and 14 patients IL-2. An additional 40 patients subsequently received IL-2. Five taxol patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 were excluded from the comparison as similar patients were ineligible for the IL-2 studies. There were more patients in the IL-2 groups with non-liver/lung metastases and ECOG PS 0 than in the taxol group. Six (43%) of concurrent IL-2 patients responded [complete response (CR)=14%; partial response (PR)=29%]. The response rate for all IL-2-treated patients was 22% (CR ± 7%, PR ± 15%). The response rate to IL-2 was higher in cases with ECOG PS 0, time to treatment <12 months, and no prior chemotherapy. The median time to progression for the concurrent IL-2 group was 4.5 months (4.0 months for all IL-2 patients) and 2.5 months for taxol patients. Median survival for concurrent IL-2 patients was 12.5 months (12 months for all IL-2 patients) and 10 months for taxol patients. Durable remissions resulted in a 21% overall survival at 40 months for all IL-2 patients. These data show prolonged time to treatment failure after treatment with IL-2 and evidence of improvement in survival for patients eligible for Phase II studies.

KW - Interferon-a

KW - Interleukin-2

KW - Lymphocyte-activated killer cells

KW - Renal cell carcinoma

KW - Taxol

UR - http://www.scopus.com/inward/record.url?scp=0027315266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027315266&partnerID=8YFLogxK

M3 - Article

C2 - 8101452

AN - SCOPUS:0027315266

VL - 13

SP - 275

EP - 281

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1053-8550

IS - 4

ER -